Concord Biotech announced its Q2 FY25 results today, showcasing strong financial performance with notable growth in both revenue and profitability. The company reported a robust increase in revenue from operations, rising by 18.2% Year-over-Year (YoY) to ₹310.18 crore, driven by increased market demand and expanding product reach. Profit After Tax (PAT) also saw a significant 18% YoY increase, reaching ₹95.74 crore. These results reflect Concord Biotech’s steady growth trajectory, positioning it well in the biotech industry as it continues to capitalize on rising demand for its offerings.
Quarterly Performance (Q2 FY25):
- Revenue from Operations: ₹310.18 crore, an increase of 18.2% Year-over-Year (YoY) from ₹262.35 crore in Q2 FY24.
- Profit After Tax (PAT): ₹95.74 crore, up by 18% YoY compared to ₹81.02 crore in Q2 FY24.
Sequential Growth (QoQ)
- Revenue from Operations: Up 43.7% from ₹215.80 crore in Q1 FY25.
- PAT: Increased by 61% from ₹59.59 crore in Q1 FY25.
This solid YoY growth in revenue from operations indicates Concord Biotech’s expanding market presence and increasing demand for its products, while the sequential growth highlights a strong quarter-over-quarter recovery.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
